<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944500</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000327</org_study_id>
    <nct_id>NCT02944500</nct_id>
  </id_info>
  <brief_title>Saxenda: Underlying Mechanisms and Clinical Outcomes</brief_title>
  <official_title>Saxenda: Underlying Mechanisms and Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to investigate the effect of treatment with the study drug&#xD;
      Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food&#xD;
      intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD response to food cues</measure>
    <time_frame>5 weeks</time_frame>
    <description>effect size of BOLD response to food cues in the brain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide followed by placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <arm_group_label>Liraglutide followed by placebo</arm_group_label>
    <arm_group_label>Placebo followed by liraglutide</arm_group_label>
    <other_name>Saxenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Liraglutide followed by placebo</arm_group_label>
    <arm_group_label>Placebo followed by liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese: BMI&gt; 30 kg/m2 or &gt;27 kg/m2 with comorbidities (including but not limited to&#xD;
             insulin resistance, hypertension, dyslipidemia, cardiovascular disease, stroke, sleep&#xD;
             apnea, gallbladder disease, hyperuricemia and gout, and osteoarthritis).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are breastfeeding, pregnant, or wanting to become pregnant.&#xD;
&#xD;
          2. Women using metal IUD&#xD;
&#xD;
          3. Any change in the dosage of hormonal contraceptive medications (birth control pills,&#xD;
             implanon). Subjects should remain on same medication/ same dose during the time of the&#xD;
             entire study.&#xD;
&#xD;
          4. Moderate (creatinine clearance of 30-59 ml/min) and severe renal impairment&#xD;
             (creatinine clearance below 30 ml/min) and end-stage renal disease&#xD;
&#xD;
          5. Moderate, or severe hepatic impairment&#xD;
&#xD;
          6. Hypersensitivity to the active substance or any of the excipients in liraglutide&#xD;
&#xD;
          7. History of diabetic ketoacidosis&#xD;
&#xD;
          8. Congestive heart failure&#xD;
&#xD;
          9. EKG abnormalities (as listed above)&#xD;
&#xD;
         10. Inflammatory conditions like inflammatory bowel disease, Rheumatoid arthritis etc&#xD;
&#xD;
         11. Gastroparesis&#xD;
&#xD;
         12. Pancreatitis&#xD;
&#xD;
         13. Gallstones- as they may cause increased risk of pancreatitis&#xD;
&#xD;
         14. Alcohol consumption- the maximum quantity for men is 140g-210g per week. For women,&#xD;
             the range is 84g-140g per week or drinking as consuming no more than two drinks a day&#xD;
             for men and one for women. Alcohol can cause increased risk of pancreatitis and&#xD;
             hypoglycemia.&#xD;
&#xD;
         15. Untreated thyroid disease like hypothyroidism or hyperthyroidism&#xD;
&#xD;
         16. Subjects taking the following medications: warfarin, steroids (inhaled or systemic due&#xD;
             to reduced hypoglycemic effect), and subjects on other hormones (LHRH analogs etc).&#xD;
&#xD;
         17. Subjects on any oral anti-diabetic agent except metformin&#xD;
&#xD;
         18. Personal or family history of MEN II or medullary thyroid cancer&#xD;
&#xD;
         19. Subjects with any type of bioimplant activated by mechanical, electronic, or magnetic&#xD;
             means (e.g. cochlear implants, pacemakers, neuron or biostimulators, electronic&#xD;
             infusion pumps, etc.)&#xD;
&#xD;
         20. Subjects with any type of metallic implant that could potentially be displaced or&#xD;
             damaged during MRI, such as aneurysm clips, metallic skull plates, surgical implants&#xD;
             etc. or metal containing tattoos&#xD;
&#xD;
         21. Anxiety of small spaces and/or claustrophobia&#xD;
&#xD;
         22. Uncontrolled cardiac impairment, circulatory impairment, or inability to perspire&#xD;
             (poor thermoregulatory function)&#xD;
&#xD;
         23. Significant sensory or motor impairment&#xD;
&#xD;
         24. Epilepsy, particularly photo-sensitive epilepsy, which may place the individual at a&#xD;
             higher risk for adverse events during fMRI scanning with visual stimulation&#xD;
&#xD;
         25. Subjects with neurological or psychological problems which may interfere with or&#xD;
             complicate testing (e.g. presence of titubation)&#xD;
&#xD;
         26. Body weight above the limitation of the MRI scanning table (330lbs/150 Kg) or body&#xD;
             dimensions that could difficult the performance of the scan.&#xD;
&#xD;
         27. Subjects who cannot adhere to the experimental protocol for any reason&#xD;
&#xD;
         28. Anemia with Hgb less than 10&#xD;
&#xD;
         29. Uncontrolled infectious diseases (e.g. HIV, hepatitis, chronic infections etc)&#xD;
&#xD;
         30. Any uncontrolled endocrine condition, e.g Cushing's, Acromegaly, etc&#xD;
&#xD;
         31. Any cancers or lymphoma&#xD;
&#xD;
         32. Eating disorders like anorexia, bulimia&#xD;
&#xD;
         33. Severe hypertriglyceridemia (triglycerides &gt;500 mg/dl)&#xD;
&#xD;
         34. Weight loss surgery or gastrectomy&#xD;
&#xD;
         35. Any changes in medications that affect brain function, e.g. anti-depressants,&#xD;
             anti-psychotics, anti-anxiety, anti-seizure medications, antihypertensives etc&#xD;
             (subjects should remain on same medication/ same dose during the time of the entire&#xD;
             study).&#xD;
&#xD;
         36. Vegetarians- as food images presented will include numerous non-vegetarian items and&#xD;
             thus will not be appealing as high calorie food items.&#xD;
&#xD;
         37. Suicidality, as measured by the MSSI at screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center General Clinical Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Christos Mantzoros</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Brain</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Patient data is protected by HIPAA. Results will be published in a peer-reviewed journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

